Azenta Inc (AZTA)vsBecton Dickinson and Company (BDX)
AZTA
Azenta Inc
$21.86
+2.58%
HEALTHCARE · Cap: $1.01B
BDX
Becton Dickinson and Company
$158.27
+1.51%
HEALTHCARE · Cap: $56.49B
Smart Verdict
WallStSmart Research — data-driven comparison
Becton Dickinson and Company generates 3585% more annual revenue ($21.92B vs $595.03M). BDX leads profitability with a 8.0% profit margin vs -10.1%. AZTA appears more attractively valued with a PEG of 0.53. BDX earns a higher WallStSmart Score of 61/100 (C+).
AZTA
Buy57
out of 100
Grade: C
BDX
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-12.2%
Fair Value
$27.14
Current Price
$21.86
$5.28 premium
Margin of Safety
+36.9%
Fair Value
$286.42
Current Price
$158.27
$128.15 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 80.0% year-over-year
Earnings expanding 8778.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Large-cap with strong market position
Reasonable price relative to book value
Earnings expanding 28.6% YoY
Areas to Watch
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
ROE of 1.5% — below average capital efficiency
Currently unprofitable
Moderate valuation
1.6% revenue growth
ROE of 7.0% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZTA
The strongest argument for AZTA centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 80.0% demonstrates continued momentum. PEG of 0.53 suggests the stock is reasonably priced for its growth.
Bull Case : BDX
The strongest argument for BDX centers on Market Cap, Price/Book, EPS Growth. PEG of 1.16 suggests the stock is reasonably priced for its growth.
Bear Case : AZTA
The primary concerns for AZTA are P/E Ratio, Market Cap, Return on Equity.
Bear Case : BDX
The primary concerns for BDX are P/E Ratio, Revenue Growth, Return on Equity.
Key Dynamics to Monitor
AZTA profiles as a hypergrowth stock while BDX is a value play — different risk/reward profiles.
AZTA carries more volatility with a beta of 1.40 — expect wider price swings.
AZTA is growing revenue faster at 80.0% — sustainability is the question.
BDX generates stronger free cash flow (549M), providing more financial flexibility.
Bottom Line
BDX scores higher overall (61/100 vs 57/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Azenta Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Azenta Inc. is a leading provider of sample management solutions and life science tools, specializing in enhancing laboratory efficiencies for the biotechnology and pharmaceutical sectors. Leveraging innovative automated solutions, biorepository services, and advanced storage technologies, the company empowers clients to accelerate drug discovery while maintaining strict regulatory compliance. With a strong focus on cutting-edge technology and collaborative partnerships, Azenta is strategically positioned to capitalize on growth opportunities within the expanding global life sciences market. Its unwavering commitment to advancing scientific research through sophisticated products further reinforces its competitive edge in biobanking and sample management.
Visit Website →Becton Dickinson and Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?